rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LIFE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      aTyr Pharma (ATYR) Stock Fair Value Moves Lower As Phase III Funding Risks Loom
      Nov 14Yahoo FinanceLIFE
      aTyr Pharma regains compliance with Nasdaq minimum bid price rule
      Nov 13Investing.comLIFE
      aTyr Pharma files prospectus to sell up to $79.99 million in common stock
      Nov 6Investing.comLIFE
      Piper Sandler lowers aTyr Pharma stock price target on valuation
      Nov 6Investing.comLIFE
      Atyr Pharma: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceLIFE
      aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update
      Nov 5Yahoo FinanceLIFE
      aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

      Peer-reviewed publication reinforces efzofitimod’s differentiated profile and potential to advance pulmonary sarcoidosis care.SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of results from the Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efz

      Oct 29Yahoo FinanceLIFE
      aTyr Pharma announces 1-for-40 reverse stock split effective October 28
      Oct 27Investing.comLIFE
      aTyr Pharma to implement 1-for-40 reverse stock split
      Oct 27Investing.comLIFE
      aTyr Pharma Announces One-for-40 Reverse Stock Split
      Oct 27Yahoo FinanceLIFE
      aTyr Pharma partners with Einstein on cancer research
      Oct 19Investing.comLIFE
      aTyr Pharma Announces Research Collaboration with Montefiore Einstein
      Oct 19Yahoo FinanceLIFE
      aTyr Pharma publishes ATYR0101 anti-fibrotic study results
      Oct 13Investing.comLIFE
      Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease - aTyr Pharma (NASDAQ:ATYR)

      aTyr Pharma reached FDA alignment on a Phase 3 study for efzofitimod to treat pulmonary sarcoidosis, beginning in Q4 2026.

      Sep 24BenzingaLIFE
      Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease

      aTyr Pharma Inc. (NASDAQ:ATYR) secured a formal agreement with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 study protocol for its lead therapeutic candidate, efzofitimod. Following this regulatory alignment, the company prepares to initiate study-related activities across the U.S. and Europe in the fourth quarter of 2026. Phase 3 Trial Design And Endpoints The upcoming Phase 3 clinical trial aims to assess both the overall safety and effectiveness of efzofitimod in individu

      Sep 24Yahoo FinanceLIFE
      aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis

      aTyr Pharma plans to begin study-related activities in the fourth quarter of 2026 after reaching FDA alignment on a global Phase 3 efzofitimod trial, although further development will require additional capital. Key Investor TakeawaysaTyr Pharma (NASDAQ:ATYR) has reached alignment with the FDA on the protocol for a Phase 3 efzofitimod study in pulmonary sarcoidosis.

      Sep 24Yahoo FinanceLIFE
      Why is aTyr Pharma stock surging today?
      Sep 24Investing.comLIFE
      Why is aTyr Pharma stock rallying today?
      Sep 24Investing.comLIFE
      aTyr Pharma reaches FDA alignment on phase 3 sarcoidosis trial
      Sep 24Investing.comLIFE
      aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

      Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activities in the fourth quarter of 2026. SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, toda

      Sep 24Yahoo FinanceLIFE
      Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight
      Sep 8Yahoo FinanceLIFE
      aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

      Company anticipates response from FDA by mid-September 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease.SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today provided an update on the expected timing

      Sep 1Yahoo FinanceLIFE

      This is the newest page. Registered accounts read further back.